Trials / Terminated
TerminatedNCT04805671
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants With Mild or Moderate COVID-19 (STAMP)
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 399 (actual)
- Sponsor
- Invivyd, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This placebo controlled study is intended to generate safety and efficacy data in order to provide a treatment option for COVID-19 in patients with a high risk of disease progression based on age or co-morbid medical conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADG20 | Single dose of ADG20 |
| DRUG | Normal saline | Single dose of normal saline |
Timeline
- Start date
- 2021-07-26
- Primary completion
- 2022-02-10
- Completion
- 2022-11-03
- First posted
- 2021-03-18
- Last updated
- 2024-02-06
- Results posted
- 2024-02-06
Locations
68 sites across 11 countries: Argentina, Brazil, Bulgaria, Germany, Greece, Hungary, Moldova, Poland, Romania, South Africa, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04805671. Inclusion in this directory is not an endorsement.